Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

Abstract Background Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II study assessed the clinical benefit of rebamipide in reducing the inci...

Full description

Bibliographic Details
Main Authors: T. Yokota, T. Ogawa, S. Takahashi, K. Okami, T. Fujii, K. Tanaka, S. Iwae, I. Ota, T. Ueda, N. Monden, K. Matsuura, H. Kojima, S. Ueda, K. Sasaki, Y. Fujimoto, Y. Hasegawa, T. Beppu, H. Nishimori, S. Hirano, Y. Naka, Y. Matsushima, M. Fujii, M. Tahara
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Cancer
Subjects:
Chemoradiotherapy
Head and neck cancer
Oral mucositis
Rebamipide liquid
Randomized
Placebo-controlled
Online Access:http://link.springer.com/article/10.1186/s12885-017-3295-4

Internet

http://link.springer.com/article/10.1186/s12885-017-3295-4

Similar Items